Rallybio (RLYB) Enterprise Value (2020 - 2026)
Rallybio (RLYB) posted Enterprise Value of -$46.8 million for Q1 2026, up 14.51% sequentially from -$54.7 million in Q4 2025, and up 14.13% YoY from -$41.0 million in Q1 2025.
Rallybio (RLYB) Enterprise Value (2020 - 2026) Analysis & Trends
Rallybio has reported Enterprise Value for 7 years, with the latest figure at -$46.8 million in Q1 2026.
- Quarterly Enterprise Value rose 14.13% year-over-year to -$46.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.8 million (up 14.13% YoY) and the FY2025 annual result came in at -$54.7 million, up 16.45% from the prior year.
- Enterprise Value improved to -$46.8 million in Q1 2026 per RLYB's latest filing, from -$54.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$45.7 million in Q2 2025 and troughed at -$169.0 million in Q4 2022.
- A 5-year average of -$100.8 million and a median of -$94.2 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 558.28% in 2022, then surged 48.37% in 2025.
- Over 5 years, Enterprise Value stood at -$169.0 million in 2022, then surged by 34.95% to -$109.9 million in 2023, then soared by 40.41% to -$65.5 million in 2024, then gained by 16.45% to -$54.7 million in 2025, then grew by 14.51% to -$46.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$46.8 million, -$54.7 million, and -$59.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Rallybio | 95.20 Mn | 95.20 Mn | - | -92.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.85 Mn |
| Mar 31, 2026 | -46.80 Mn |
| Dec 31, 2025 | -54.74 Mn |
| Sep 30, 2025 | -59.32 Mn |
| Jun 30, 2025 | -45.75 Mn |
| Mar 31, 2025 | -54.50 Mn |
| Dec 31, 2024 | -65.51 Mn |
| Sep 30, 2024 | -75.14 Mn |
| Jun 30, 2024 | -88.61 Mn |
| Mar 31, 2024 | -94.18 Mn |
| Dec 31, 2023 | -109.93 Mn |
| Sep 30, 2023 | -121.38 Mn |
| Jun 30, 2023 | -137.84 Mn |
| Mar 31, 2023 | -150.39 Mn |
| Dec 31, 2022 | -168.99 Mn |
| Sep 30, 2022 | -132.42 Mn |
| Jun 30, 2022 | -147.37 Mn |
| Mar 31, 2022 | -161.41 Mn |
| Dec 31, 2021 | -175.33 Mn |
| Sep 30, 2021 | -186.98 Mn |